Author pages are created from data sourced from our academic publisher partnerships and public sources.
Renin–Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data
- Iris E. Beldhuis, Koen W. Streng, +5 authors K. Damman
- Circulation. Heart failure
- 1 February 2017
Background— Renin–angiotensin aldosterone system (RAAS) inhibitors significantly improve outcome in heart failure (HF) patients with reduced ejection fraction (HFREF), irrespective of the occurrence… Expand
Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
OBJECTIVES This study investigated the association between baseline renal function and the net benefit of spironolactone in patients with heart failure (HF) with a preserved ejection fraction… Expand
Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction
Background: Levels of cTn (cardiac troponin) are frequently elevated in patients with heart failure (HF) and reduced ejection fraction (EF) and correlate with the risk for mortality. However, factors… Expand
Trajectories of Changes in Renal Function in Patients with Acute Heart Failure.
- Iris E. Beldhuis, Koen W. Streng, +13 authors K. Damman
- Journal of cardiac failure
- 15 July 2019
AIMS Changes in renal function have been associated with differential outcome in patients with acute heart failure (HF). However, individual trajectories of changes in renal function are unknown and… Expand
Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
OBJECTIVES The authors examined efficacy and safety of spironolactone by age in the Americas region (N = 1,767) of the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an… Expand
P6507Factors associated with troponin elevation and risk of cardiac events in patients with heart failure and preserved ejection fraction